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Abstract
Background: Nontuberculous mycobacterial (NTM) infections cause morbidity worldwide. They are difficult to diagnose in
resource-limited regions, and most patients receive empiric treatment for tuberculosis (TB). Our objective here is to evaluate
the potential impact of NTM diseases among patients treated presumptively for tuberculosis in Mali.
Methods: We re-evaluated sputum specimens among patients newly diagnosed with TB (naı ¨ve) and those previously
treated for TB disease (chronic cases). Sputum microscopy, culture and Mycobacterium tuberculosis drug susceptibility
testing were performed. Identification of strains was performed using molecular probes or sequencing of secA1 and/or 16S
rRNA genes.
Results: Of 142 patients enrolled, 61 (43%) were clinically classified as chronic cases and 17 (12%) were infected with NTM.
Eleven of the 142 (8%) patients had NTM disease alone (8 M. avium,2M. simiae and 1 M. palustre). All these 11 were from
the chronic TB group, comprising 11/61 (18%) of that group and all were identified as candidates for second line treatment.
The remaining 6/17 (35.30%) NTM infected patients had coinfection with M. tuberculosis and all 6 were from the TB
treatment naı ¨ve group. These 6 were candidates for the standard first line treatment regimen of TB. M. avium was identified
in 11 of the 142 (8%) patients, only 3/11 (27.27%) of whom were HIV positive.
Conclusions: NTM infections should be considered a cause of morbidity in TB endemic environments especially when
managing chronic TB cases to limit morbidity and provide appropriate treatment.
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Introduction
Nontuberculous mycobacterial (NTM) infections cause morbid-
ity worldwide [1]. Currently more than 125 different types of
NTM exist in the environment. Those implicated in human
disease can produce nonspecific symptoms [2], with clinical
manifestations ranging from no symptoms or signs to destructive
or even fatal disease. When symptoms and signs occur, they are
often indistinguishable clinically and radiographically from those
caused by Mycobacterium tuberculosis [3]. However, the pattern of
resistance and treatment outcomes for NTM disease can be
significantly different from TB, resulting in different implications
for public health [4].
Though widely recognized for causing symptomatic disease in
developed countries, the role of NTM in pulmonary or systemic
disease in developing countries is not well described. This is largely
attributable to lack of diagnostic facilities to culture and identify
mycobacteria. Since TB is usually endemic and life threatening in
these areas, patients are presumptively treated for TB.
At present, there is no specific information regarding the role of
NTM in causing infection or disease in Mali, where this study was
conducted. Patients are treated based on sputum smear exams
using standard first and second line TB therapy depending on
clinical criteria in conjunction with World Health Organization
(WHO) guidelines [5]. As NTM are often resistant to first-line
anti-TB medication, presumably many of these cases would be
considered treatment failures, and subsequently treated for multi-
drug resistant (MDR) disease. In this study, we evaluated a cross
section of either naı ¨ve or chronic TB patients for NTM infection
alone or a coinfection with Mycobacterium tuberculosis (M.tb). For
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drugs and HIV status.
Since NTM are ubiquitous in the environment, infection and
disease due to NTM were differentiated by clinical evidence based
on the American Thoracic Society (ATS) criteria [6].
Methods
Ethics Statement
Patients were recruited on protocols approved by the Institu-
tional Review Board of the National Institutes for Health (NIH),
USA and the University of Bamako’s Ethic Committee in Mali.
The protocols were conducted in compliance with all international
standards applicable to human studies, including written informed
consent obtained from all the volunteers.
Setting/Participants
The study took place at the HIV/TB Research Project,
SEREFO, of the University of Bamako, in Mali. The participants
of this study represent a cross section of TB treatment-naı ¨ve and
chronic TB patients identified in the study clinics by the study
clinicians from March 1, 2004 to November 30, 2009. Patients
were recruited consecutively on protocols. The city of Bamako is
administratively divided into six municipalities each with a local
referral health center capable of diagnosing and treating TB
patients. These centers refer TB treatment failure cases to the
main TB clinic of the city at Point-G hospital.
Naı ¨ve patients were recruited directly from one of the 6 local
centers. Patients who had sputum smear positive disease were
referred to the study team by their physician at the referral center.
All chronic patients presenting to the TB Clinic at Point-G
Hospital (the only center specialized in the treatment of chronic
TB and MDR-TB in the country) during the study period were
referred to the research team.
Study Design
This was a clinic-based, cohort design, in which all patients seen
for presumptive TB (at least 1 sputum smear positive at the referral
center and no history of TB treatment, (naı ¨ve cases) or for TB
treatment failure (with at least 2 sputum smears positives after 9–
13 months of treatment (chronic cases) during the study period
were offered enrollment. Standardized interviews accompanied by
physical examination were conducted and 3 consecutive early
morning sputa were collected on 3 consecutive days. The three
consecutives sputa (in three days) for the study purposes were
collected before commencing treatment for naive patients or
retreatment for chronic patients. The sputa were self collected
each morning by the patients and then immediately transported to
the study clinic. The sputum collection was not repeated during
patients’ treatment or retreatment.
Blood for HIV testing was obtained from each volunteer. The
variables collected during the physical exam for each participant
were: age, sex, occupation, symptoms and the medical history
including previous treatments.
TB Treatment Regimen
Patients naive to treatment received the standard TB regimen
from their physicians (Table 1). Those with positive sputum smears
after 5 months of the standard regimen received the retreatment
regimen while those with sputum smears positive after 13 months
(5 months of standard regimen and 8 months of re-treatment
regimen) received the second line treatment (Table 1). Those
completing the retreatment regimen, receiving or commencing the
second line regimen at enrollment are referred to, as chronic TB
patients.
Microbiology Testing
All samples were processed at the BSL-3 facility in Bamako,
Mali unless mentioned otherwise.
Sputum specimens were decontaminated by the N-acetyl-L-
cystein/sodium hydroxide method. The sediment was used to
perform sputum smears (fluorescent Auramine Rhodamine
staining) and to inoculate cultures. Culture was performed using
Mycobacteria Growth Indicator Tubes, (MGIT, BD Sparks, MD,
USA) and selective 7H11 Middlebrook agar plate. The cultures
were incubated in CO2 for 42 days before being reported as
negative. When a possible NTM was isolated on the plate, the
colonies were sub-cultured onto new plates and the old plate was
re-incubated until day 42.
Species Typing
Nucleic acid probes (AccuProbe, Gen-Probe, San Diego CA.
USA) for M. tuberculosis complex (MTBC), M. avium complex
(MAC), M. intracellulare, M. gordonae and M. kansasii were used for
initial identification. Eight samples, not identified by AccuProbe
were sequenced and identified as M. kumamotonense, M. kubicae, M.
morokaense, M. fortuitum, M. simiae or M. palustre. DNA was amplified
by PCR followed by sequencing of the secA1 gene [7] and/or full
sequencing of the 16S rRNA gene with ‘‘MicroSeq Full Gene 16S
rRNA Bacterial Isolation Sequencing kit’’ (Applied Biosystems,
Foster City, Calif.) according to the manufacturer’s protocol. Both
phenotypic and genotypic characteristics were taken into consid-
eration when identifying the isolate. The macroscopic colonial
morphologies were consistent with the sequencing identifications
for all of the isolates. Sequencing was performed at the National
Institutes of Health, Bethesda, Maryland.
To distinguish M. tuberculosis from M. africanum strains,
spoligotyping was performed using a commercial kit (Isogen Life
Science, De Meern, The Netherlands) [8]. Strains comparison was
made with databases available from the New York City
Department of Health (NYC) and SPOTCLUST (SpolDB4-
based).
HIV Testing
‘‘Determine HIV-1/2’’ (Abbott, Tokyo, Japan), Genscreen and
Western Blot kits (BioRad, Paris, France) were used to determine
the HIV serological status of the volunteers.
Drug susceptibility tests
Susceptibility testing of M. tuberculosis was performed using
BACTEC-MGIT 960 SIRE Kits (Franklin Lakes, NJ, USA). All
MDR-TB isolates were sent to National Jewish Hospital, Denver,
Colorado for confirmation and to perform second line drug testing
by agar proportion method [9].
Statistical analysis
The chi-square test with GraphPad Prism version 5 (GraphPad
Software, San Diego, CA, USA) was used for the statistical
analyses. A p-value less than 0.05 was considered significant.
Results
During the study period, a total of 142 patients were referred to
the study investigators and all were enrolled. Eighty-one patients
(57.04%) were naı ¨ve to treatment (naı ¨ve group) and were recruited
from the referral centers; 61 (42.96%) had a history of treatment
with TB standard regimen or re-treatment regimen and were
Nontuberculous Mycobacteria and TB Treatment
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36902T
a
b
l
e
1
.
M
y
c
o
b
a
c
t
e
r
i
a
l
s
p
e
c
i
e
s
i
s
o
l
a
t
e
d
,
d
e
m
o
g
r
a
p
h
i
c
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
,
s
y
m
p
t
o
m
s
a
n
d
t
r
e
a
t
m
e
n
t
a
s
s
i
g
n
e
d
t
o
e
a
c
h
p
a
t
i
e
n
t
.
P
a
t
i
e
n
t
A
g
e
G
e
n
d
e
r
H
I
V
S
t
a
t
u
s
O
c
c
u
p
a
t
i
o
n
S
y
m
p
t
o
m
s
A
F
B
S
m
e
a
r
A
F
B
C
u
l
t
u
r
e
N
T
M
I
s
o
l
a
t
e
d
C
o
-
i
n
f
e
c
t
i
o
n
M
o
l
e
c
u
l
a
r
I
D
t
o
o
l
s
u
s
e
d
T
r
e
a
t
m
e
n
t
a
t
t
i
m
e
o
f
e
n
r
o
l
l
m
e
n
t
$
1
3
1
M
a
l
e
N
e
g
D
r
i
v
e
r
W
e
i
g
h
t
l
o
s
s
,
f
e
v
e
r
,
h
e
a
d
a
c
h
e
N
o
A
F
B
P
o
s
M
.
a
v
i
u
m
M
.
t
b
P
r
o
b
e
S
t
a
n
d
a
r
d
r
e
g
i
m
e
n
*
2
5
3
M
a
l
e
N
e
g
H
e
a
l
t
h
T
e
c
h
.
C
o
u
g
h
,
w
e
i
g
h
t
l
o
s
s
,
f
e
v
e
r
,
c
h
e
s
t
p
a
i
n
M
a
n
y
A
F
B
P
o
s
M
.
a
v
i
u
m
M
.
m
o
r
i
o
k
a
e
n
s
e
@
M
.
a
f
P
r
o
b
e
S
t
a
n
d
a
r
d
r
e
g
i
m
e
n
S
e
q
u
e
n
c
i
n
g
3
1
8
M
a
l
e
N
e
g
C
o
n
s
t
r
u
c
t
i
o
n
w
o
r
k
e
r
C
o
u
g
h
,
f
e
v
e
r
,
c
h
e
s
t
p
a
i
n
F
e
w
A
F
B
P
o
s
M
.
k
u
b
i
c
a
e
M
.
a
f
S
e
q
u
e
n
c
i
n
g
S
t
a
n
d
a
r
d
r
e
g
i
m
e
n
4
2
4
M
a
l
e
N
e
g
T
a
i
l
o
r
C
o
u
g
h
,
w
e
i
g
h
t
l
o
s
s
,
f
e
v
e
r
F
e
w
A
F
B
P
o
s
M
.
k
u
m
a
m
o
t
o
n
e
n
s
e
@
M
.
f
o
r
t
u
i
t
u
m
M
.
t
b
S
e
q
u
e
n
c
i
n
g
S
t
a
n
d
a
r
d
r
e
g
i
m
e
n
S
e
q
u
e
n
c
i
n
g
5
3
6
M
a
l
e
P
o
s
D
r
i
v
e
r
C
o
u
g
h
,
w
e
i
g
h
t
l
o
s
s
,
c
h
e
s
t
p
a
i
n
,
d
y
s
p
n
e
a
,
a
n
o
r
e
x
i
a
F
e
w
A
F
B
P
o
s
M
.
a
v
i
u
m
M
.
t
b
P
r
o
b
e
S
t
a
n
d
a
r
d
r
e
g
i
m
e
n
6
3
6
M
a
l
e
N
e
g
C
l
e
a
n
e
r
C
o
u
g
h
,
f
e
v
e
r
,
a
n
o
r
e
x
i
a
M
a
n
y
A
F
B
P
o
s
M
.
g
o
r
d
o
n
a
e
M
.
a
f
P
r
o
b
e
S
t
a
n
d
a
r
d
r
e
g
i
m
e
n
7
5
1
M
a
l
e
N
e
g
F
a
r
m
e
r
C
o
u
g
h
,
f
e
v
e
r
,
a
n
o
r
e
x
i
a
,
d
y
s
p
n
e
a
,
c
h
e
s
t
p
a
i
n
F
e
w
A
F
B
P
o
s
M
.
a
v
i
u
m
N
o
n
e
P
r
o
b
e
S
e
c
o
n
d
l
i
n
e
t
r
e
a
t
m
e
n
t
8
5
6
M
a
l
e
N
e
g
A
c
c
o
u
n
t
s
m
a
n
a
g
e
r
D
y
s
p
n
e
a
,
e
p
i
g
a
s
t
r
i
c
p
a
i
n
N
o
A
F
B
P
o
s
M
.
a
v
i
u
m
N
o
n
e
P
r
o
b
e
S
e
c
o
n
d
l
i
n
e
t
r
e
a
t
m
e
n
t
9
3
1
M
a
l
e
P
o
s
T
a
i
l
o
r
C
o
u
g
h
,
w
e
i
g
h
t
l
o
s
s
,
f
e
v
e
r
M
a
n
y
A
F
B
P
o
s
M
.
a
v
i
u
m
N
o
n
e
P
r
o
b
e
S
e
c
o
n
d
l
i
n
e
t
r
e
a
t
m
e
n
t
1
0
3
5
M
a
l
e
N
e
g
F
a
r
m
e
r
C
o
u
g
h
,
f
e
v
e
r
,
h
e
m
o
p
t
y
s
i
s
M
a
n
y
A
F
B
P
o
s
M
.
s
i
m
i
a
e
N
o
n
e
S
e
q
u
e
n
c
i
n
g
S
e
c
o
n
d
l
i
n
e
t
r
e
a
t
m
e
n
t
1
1
3
4
M
a
l
e
N
e
g
A
c
c
o
u
n
t
a
n
t
W
a
s
t
i
n
g
,
c
o
u
g
h
,
r
a
l
e
s
M
a
n
y
A
F
B
P
o
s
M
.
a
v
i
u
m
N
o
n
e
P
r
o
b
e
S
e
c
o
n
d
l
i
n
e
t
r
e
a
t
m
e
n
t
1
2
4
6
M
a
l
e
P
o
s
T
a
i
l
o
r
C
o
u
g
h
,
w
e
i
g
h
t
l
o
s
s
,
c
h
e
s
t
p
a
i
n
,
D
y
s
p
n
e
a
,
a
n
o
r
e
x
i
a
M
a
n
y
A
F
B
P
o
s
M
.
a
v
i
u
m
N
o
n
e
P
r
o
b
e
S
e
c
o
n
d
l
i
n
e
t
r
e
a
t
m
e
n
t
1
3
6
5
M
a
l
e
N
e
g
T
e
a
c
h
e
r
W
e
i
g
h
t
l
o
s
s
,
c
o
n
j
u
n
c
t
i
v
a
l
p
a
l
o
r
,
w
h
e
e
z
i
n
g
N
o
A
F
B
P
o
s
M
.
a
v
i
u
m
N
o
n
e
P
r
o
b
e
S
e
c
o
n
d
l
i
n
e
t
r
e
a
t
m
e
n
t
1
4
5
0
F
e
m
a
l
e
N
e
g
H
o
u
s
e
w
i
f
e
C
o
u
g
h
,
f
e
v
e
r
,
d
y
p
s
n
e
a
,
c
h
e
s
t
p
a
i
n
F
e
w
A
F
B
P
o
s
M
.
s
i
m
i
a
e
N
o
n
e
S
e
q
u
e
n
c
i
n
g
S
e
c
o
n
d
l
i
n
e
t
r
e
a
t
m
e
n
t
1
5
4
0
M
a
l
e
N
e
g
C
a
t
t
l
e
b
r
e
e
d
e
r
C
o
u
g
h
,
H
e
a
d
a
c
h
e
,
a
n
o
r
e
x
i
a
M
a
n
y
A
F
B
P
o
s
M
.
p
a
l
u
s
t
r
e
N
o
n
e
S
e
q
u
e
n
c
i
n
g
R
e
t
r
e
a
t
m
e
n
t
r
e
g
i
m
e
n
1
6
7
3
M
a
l
e
N
e
g
C
u
l
t
i
v
a
t
o
r
C
o
u
g
h
,
w
e
i
g
h
t
l
o
s
s
,
f
e
v
e
r
M
a
n
y
A
F
B
P
o
s
M
.
a
v
i
u
m
N
o
n
e
P
r
o
b
e
R
e
t
r
e
a
t
m
e
n
t
r
e
g
i
m
e
n
1
7
4
4
M
a
l
e
N
e
g
M
e
c
h
a
n
i
c
C
o
u
g
h
,
f
e
v
e
r
F
e
w
A
F
B
P
o
s
M
.
a
v
i
u
m
N
o
n
e
P
r
o
b
e
S
e
c
o
n
d
l
i
n
e
t
r
e
a
t
m
e
n
t
@
M
y
c
o
b
a
c
t
e
r
i
u
m
s
p
e
c
i
e
s
m
o
s
t
c
l
o
s
e
l
y
r
e
l
a
t
e
d
;
*
P
a
t
i
e
n
t
s
w
e
r
e
n
a
ı
¨
v
e
t
o
T
B
t
r
e
a
t
m
e
n
t
b
e
f
o
r
e
t
h
e
y
w
e
r
e
e
n
r
o
l
l
e
d
i
n
t
h
e
s
t
u
d
y
a
n
d
r
e
c
e
i
v
e
d
t
h
e
T
B
s
t
a
n
d
a
r
d
r
e
g
i
m
e
n
f
o
r
t
h
e
i
r
d
i
s
e
a
s
e
.
$
B
a
s
e
d
o
n
N
a
t
i
o
n
a
l
t
r
e
a
t
m
e
n
t
g
u
i
d
e
l
i
n
e
s
f
o
r
T
B
,
t
h
e
S
t
a
n
d
a
r
d
r
e
g
i
m
e
n
c
o
m
p
r
i
s
e
s
2
m
o
n
t
h
s
o
f
r
i
f
a
m
p
i
n
,
i
s
o
n
i
a
z
i
d
,
p
y
r
a
z
i
n
a
m
i
d
e
a
n
d
e
t
h
a
m
b
u
t
o
l
a
n
d
4
m
o
n
t
h
s
o
f
i
s
o
n
i
a
z
i
d
a
n
d
r
i
f
a
m
p
i
n
(
2
R
H
Z
E
/
4
R
H
)
.
P
a
t
i
e
n
t
s
w
i
t
h
s
p
u
t
u
m
s
m
e
a
r
s
p
o
s
i
t
i
v
e
a
t
m
o
n
t
h
-
5
o
f
s
t
a
n
d
a
r
d
r
e
g
i
m
e
n
,
r
e
c
e
i
v
e
1
m
o
n
t
h
o
f
r
i
f
a
m
p
i
n
,
i
s
o
n
i
a
z
i
d
,
p
y
r
a
z
i
n
a
m
i
d
e
,
e
t
h
a
m
b
u
t
o
l
a
n
d
s
t
r
e
p
t
o
m
y
c
i
n
f
o
l
l
o
w
e
d
b
y
2
m
o
n
t
h
s
o
f
r
i
f
a
m
p
i
n
,
i
s
o
n
i
a
z
i
d
,
p
y
r
a
z
i
n
a
m
i
d
e
,
e
t
h
a
m
b
u
t
o
l
a
n
d
5
m
o
n
t
h
s
o
f
r
i
f
a
m
p
i
n
,
i
s
o
n
i
a
z
i
d
a
n
d
e
t
h
a
m
b
u
t
o
l
(
2
R
H
Z
E
S
/
1
R
H
Z
E
/
5
R
H
E
c
a
l
l
e
d
r
e
-
t
r
e
a
t
m
e
n
t
r
e
g
i
m
e
n
)
.
T
h
e
s
e
c
o
n
d
l
i
n
e
t
r
e
a
t
m
e
n
t
f
o
r
c
h
r
o
n
i
c
c
a
s
e
s
(
p
a
t
i
e
n
t
s
w
i
t
h
s
p
u
t
u
m
s
m
e
a
r
s
p
o
s
i
t
i
v
e
a
f
t
e
r
r
e
-
t
r
e
a
t
m
e
n
t
r
e
g
i
m
e
n
)
c
o
m
p
r
i
s
e
s
k
a
n
a
m
y
c
i
n
,
o
f
l
o
x
a
c
i
n
,
e
t
h
i
o
n
a
m
i
d
e
a
n
d
p
y
r
a
z
i
n
a
m
i
d
e
(
3
K
O
E
t
Z
/
1
8
O
e
t
Z
)
f
o
r
M
D
R
d
i
s
e
a
s
e
.
M
.
a
f
:
M
y
c
o
b
a
c
t
e
r
i
u
m
a
f
r
i
c
a
n
u
m
;
M
.
t
b
:
M
y
c
o
b
a
c
t
e
r
i
u
m
t
u
b
e
r
c
u
l
o
s
i
s
;
N
e
g
:
n
e
g
a
t
i
v
e
;
P
o
s
:
p
o
s
i
t
i
v
e
;
A
F
B
:
a
c
i
d
-
f
a
s
t
b
a
c
i
l
l
i
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
3
6
9
0
2
.
t
0
0
1
Nontuberculous Mycobacteria and TB Treatment
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36902recruited from the Point-G hospital. These 61 were being
evaluated for or were receiving treatment of multidrug resistant
(MDR) disease. The median age of the patients was 43 years
(range 18–73 years) with 109 males and 33 females. Most of these
patients lived in Bamako or in the vicinity. NTM were isolated
from 17 out of the 142 patients (12%). NTM were less prevalent in
patients with naı ¨ve TB (6 of 81 or 7.4%) as compared to those with
chronic TB (11 of 61, or 18%) [p=0.03].
Fourteen of the 17 NTM patients (82.35%) were sputum smears
positive with auramine rhodamine staining performed in our
laboratory. All 17 were culture positive for mycobacteria on at
least 2 occasions (Table 2) and presented with clinical symptoms
consistent with TB (Table 1). The most common symptoms in
NTM infected patients were cough 13/17 cases (76.47%), fever
11/17 cases (64.7%) weight loss 8/17 cases (47.05%), chest pain
6/17 cases (35.29%), anorexia 5/17 cases (29.41%) and dyspnea
5/17 cases (29.41).
Naı ¨ve Group
All 6 of the 81 (7.4%) volunteers in the naive group infected
with NTM (including one patient with M. gordonae) were co-
infected with MTBC organisms, with 4 cases of M. tuberculosis
(sensu stricto) and 2 cases of M. africanum. In 2 of the 6 volunteers
(33.33%), we identified 3 different mycobacterial species: the first
one was infected by M. avium and M. moriokaense in addition to M.
africanum and the second one had M. fortuitum and M. kumamotonense
in addition to M. tuberculosis (Table 1). One other patient (16.67%)
had a coinfection of M. africanum with M. kubicae. All 6 co-infected
patients were receiving standard treatment for TB, but not for
NTM infection (Table 1).
Chronic Disease Group
None of the 11 patients in this group with NTM were co-
infected with MTBC (Table 1). Eight of the 11(72.73%) had MAC
infection, 2 (18.18%) had M. simiae and 1 (9.09%) was infected by
M. palustre. All these 11 patients with NTM met the ATS 2007
revised criteria [6] for NTM disease (Table 1). To the best of our
knowledge the clinical response to the diagnosis of an NTM
infection was cessation of TB treatment with no treatment being
provided for NTM disease except for one patient. Follow up data
for this patient (Patient 9 in Table 1) who had MAC infection was
available. He was treated for MAC disease but returned 8 months
later with continued clinical symptoms. Samples obtained at that
time showed a diagnosis of MDR-TB and M. avium was not
isolated.
Drug Susceptibility Testing
In the chronic disease group 22/61(36%) with presumed MDR-
TB actually had MDR disease. Six (9.83%) patients had fully
susceptible strains, 10 (16.40%) had resistance to only one
antibiotic, 11 (18.03%) had NTM disease and 12 (19.67%)
patients were culture negative. In the treatment naı ¨ve group, only
two patients (2.46%) had disease with an MDR strain as the cause
of their primary infection. MDR disease was more common in
patients who had chronic disease (22 of 61, or 36.06%) as
compared to patients who were treatment naı ¨ve cases (2 of 81 or
2.5%) [(Table 3), p,0.0001].
Microbiology Data
Sputum samples from all 81 patients in the naı ¨ve group (100%)
and 53/61 (86.89%) patients in the chronic group were sputum
smear positive for AFB. Nine of the 11 patients (81.81%)
presenting with NTM alone, had AFB positive smears (Table 2).
All 81 acute cases were culture positive while 12 out of the 61
chronic cases (20%) were culture negative (Table 3).
Among patients coinfected with more than one mycobacterium
species, colonies were clearly differentiated by culture and
confirmed by subsequent probe, sequencing or both. For Patient
4, Mycobacterium sp. most closely related to M. kumamotonense and M.
fortuitum were isolated on 2 separate visits, possibly indicating that
they were colonizers rather than pathogens in the setting of M.
tuberculosis coinfection. Sequence-based identification of mycobac-
teria in our institution is routinely performed by partial sequencing
of secA1. Full sequencing of 16S rRNA gene is performed when
secA1 sequencing does not yield a conclusive identification (usually
because of the species are not in the database). For most isolates
for which both gene targets were sequenced, the 16S rRNA
sequence homology was 99.7–99.9% and the corresponding secA1
sequences (with the exception of M. kubicae) were 99.4–100%. M.
kubicae was not present in the secA1 database and therefore could
not be evaluated.
Based on sequence analysis using 16S rRNA gene, Patient 2 had
a mycobacterial isolate 99.1% similar to M. moriokaense group and
Patient 4 had a mycobacterial isolate 99.2% similar to M.
kumamotonense. Results of secA1 sequencing were not definitive for
any of these two isolates. Because the percent similarity of these
isolates with 16S rRNA gene sequences is relatively low, we
identified them as Mycobacterium species most closely related to M.
moriokaense and kumamotonense respectively.
Interpretation of sequencing results can be controversial as there
are no clear cutoffs. However, it has been suggested that similarity
.99.5% is acceptable [10].
MAC infection seen in 11/17 (64.70%) patients was the most
prevalent in the NTM infection (Table 1 et 3).
HIV Infection
Twenty-eight of the 142 patients (19.71%) were HIV infected.
Twenty-five of the 28 (89.3%) were acute (naive) TB patients and 3
(10.7%) were chronic TB patients. This frequency of HIV in TB
patients is very close to the Mali National TB program’s report of
2009 regarding the prevalence of HIV co-infection among TB
patients, which was estimated to be 18%.
Three of the 28 (10.71%) HIV patients (1 naive case and 2
chronic cases) were infected by NTM. All 3 were infected by MAC
(Table 1). The patient from the naı ¨ve group was coinfected with
M. tuberculosis. All were receiving treatment for TB disease only
and none were receiving antiretroviral therapy at the time of TB
diagnosis. In addition, NTM infections were not more common in
the HIV patients (3/28 or 10.71%) as compared to non-HIV
infected patients (14/114 or 12.28%) [p=0.41].
Table 2. Impact of NTM on TB sputum smears or cultures.
Patients Sputum smears Sputum cultures
*Pos
#Neg *Pos
#Neg
NTM alone (NTM disease) 9 2 11 0
NTM and MTBC 5 1 6 0
MTBC alone 108 5 113 0
NTM: Nontuberculous mycobacteria; MTBC: Mycobacterium tuberculosis complex;
*Pos: positive in at least two occasions;
#Neg: negative in three occasions.
doi:10.1371/journal.pone.0036902.t002
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Nontuberculous mycobacteria are a recognized cause of
mycobacterial infection worldwide [11–13]. This is also true in
Africa, where TB is endemic [14–16]. Currently, very little data
exists on the NTM species distribution in pulmonary specimens in
Africa. Yet, it is well known that important differences in species
distribution exist between countries and regions [17–18]. Though
MAC has received attention due to its frequent occurrence in
patients with HIV, this and other NTM have been reported also in
patients with other immune suppressive diseases, in apparently
normal hosts [13,19] and smoking related chronic obstructive
pulmonary disease.
The presence of NTM in the patients with chronic TB had a
substantial impact on clinical management. Incorrect diagnosis of
pulmonary TB due to the presence of NTM led to inappropriate
or unnecessary treatment of patients with NTM isolates.
In developing countries, the presumption is that most pulmo-
nary symptoms resembling mycobacterial disease are caused by M.
tuberculosis. This largely stems from the lack of appropriate
diagnostics in resource-limited environments as well as the
endemic nature of M. tuberculosis in these areas [20–21].
Among the chronic TB cases, NTM infection was seen in 11/61
(18%) and all were receiving or were clinically empiric candidates
for MDR-TB treatment. Not only is this treatment ineffective, but
also expensive, often causing economic hardship, which can lead
to erratic treatment and the likelihood of increased resistance.
Persons infected with M. tuberculosis were in some instances
coinfected with NTM and few data are available on the
significance of such co-infections. The NTM were found with
either M. africanum or M. tuberculosis (sensu stricto) disease and were
most likely colonizers. Though it is reasonable to assume that the
patient’s symptoms were largely due to M. tuberculosis, it is unclear
whether the co-infecting NTM played a role in disease pathogen-
esis, affected time to sputum clearance or contributed to a more
chronic course of the infection. NTM are found more easily in
previously damaged or diseased tissue and that could explain why
they were isolated from patients with preexisting TB. M. avium is a
well-defined cause of infection and disease in both immunocom-
promised and otherwise normal individuals. However the role of
M. avium in the three patients (1, 2 and 5, Table 1) who were
coinfected with M. tuberculosis is unclear. One (Patient 5) was HIV
positive as well and a pathogenic role of the co-infection cannot be
discounted.
The other NTM isolated have also been associated with disease
in humans. For example, members of the M. moriokaense group
have been associated with chronic pulmonary infection [22]. M.
kumamotonense first identified in 2006 has been implicated in clinical
disease as well [23]. M. fortuitum has been implicated in
subcutaneous and prosthetic infections and is a rare cause of
pulmonary disease [24–27] except in those with chronic vomiting,
esophageal disease [6] and immunosuppression. In normal host or
those with underlying pulmonary infections, it is mainly consid-
ered to be a colonizer [11,26,28]. M. kubicae (first identified in
2000) and M. gordonae are possible contaminants [29]. M. simiae,
though a reported cause of disease is generally thought to be a
contaminant or colonizer of previously damaged tissue [29–30].
Two Patients (10 and 14, Table 1), however, met the ATS criteria
for NTM disease with M. simiae.
M. palustre was first reported in 2002, and though generally
isolated from environmental sources like fresh water streams and
veterinary samples, it has been reported as a cause of wound
infections, bacteremia [31–32] and lymphadenitis in humans [33]
Patient 15 presented with pulmonary infection with M. palustre,
which is a unique presentation reported for M. palustre. He was in
the chronic disease group and was receiving a TB re-treatment
regimen.
Only 22/61 (36%) patients in the chronic disease group actually
had MDR disease. The rest had either susceptible disease (6 or
9.83%), single antibiotic resistance (10 or 16.40%) or NTM disease
(11 or 18.03%). Without the appropriate diagnostic testing, a
minimum of 27[6+10+11]/61 (44%) patients in the chronic group
would have received inappropriate treatment. Twelve patients
(19.67%) were culture negative. It was not possible to conclude if
these culture negative patients had nonviable organisms or if they
were infected by mycobacteria that did not grow on conventional
media [34–36]. In either case these patients should likely not have
been considered candidates for treatment for MDR disease.
Including these 12 additional patients suggests that 39/61 (63%)
patients from the chronic disease group would have been receiving
an inappropriate regimen or unnecessary treatment. Most of the
18% NTM cases in the chronic group did not receive treatment
for their NTM disease, and failure to identify and treat this
etiology may lead to chronic, disabling symptoms and profound
respiratory impairment.
Our study has some limitations that could have an impact on
the results. We did not have initial laboratory data on the chronic
patients preventing us from ascertaining if they had been infected
only by an NTM or if they initially have had a coinfection with M.
tuberculosis. Also, lack of follow up limits the ability to ascertain
outcomes for patients especially with NTM disease. Finally the
true prevalence of NTM can only be gauged during a larger
epidemiological study.
Despite these limitations in our study cohort, 18% of clinically
chronic TB cases could be attributed to NTM with a predominance
Table 3. Distribution of patients in the naı ¨ve and chronic treatment groups based on culture and susceptibility results.
Culture
Negative
MTBC*
Pansensitive
MTBC with at least 1
drug resistant and not
MDR-TB MDR
# NTM@
Coinfection
(MTBC+NTM) Total
Chronic Disease
Group
12 6 10 22 11 0 61
Treatment Naı ¨ve
Group
06 9 4 2 0 6 8 1
Total 12 75 14 24 11 6 142
*M. tuberculosis complex,
#Resistant to isoniazid and rifampin,
@Nontuberculous Mycobacteria.
doi:10.1371/journal.pone.0036902.t003
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patients who fail first line and re-treatment regimens. It also
highlights the need to study NTM infections in TB endemic areas
through a larger cohort and to evaluate the impact of these
infections on TB disease. Multidrug resistance may erroneously be
suspected in these patients, and the presence of NTM in diagnostic
specimens can delay the diagnosis of pulmonary malignancies in
others. The significance of finding NTM should be thoroughly
evaluated beforetreatment is startedby applying the ATS criteria of
NTM lung disease, because when sputum is negative and bronchial
washings are positive, the odds of isolating NTM rise. Thus, careful
and repeated bacteriological examination as well as clear commu-
nication between physician and microbiologist is crucial.
Lack of access to diagnostic testing is a key barrier to
understanding these issues and achieving optimal outcomes.
However, the cost of providing these resources is nominal, when
considering the burden of inappropriate treatment. Susceptibility
testing can cost between 150–200 USD in certain areas for a basic
panel but is not readily available in many resource-limited
countries. If suboptimal management of patients who fail
treatment for TB is not acceptable in developed countries, why
should the standards be different for developing countries?
Increasingly, attention to the development of resistant strains of
M. tuberculosis is a matter of urgency to prevent inappropriate use of
antibiotics in the effort to achieve global TB control. This will only
be possible if clinicians have the necessary diagnostic information
to make correct treatment choices and if national treatment
programs have access to data required to design appropriate
programs based on their country needs.
In conclusion, our data suggest that NTM infections may play an
important rolein causing lung diseaseand impact the management of
TB in TB-endemic environments by leading to misdiagnosis and
inappropriate treatment of MDR cases particularly the clinically
‘‘chronic cases’’. This highlights the necessity to consider these
organisms when treating patients with putative TB treatment failures.
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